Grapefruit.

Grapefruit furanocoumarins inactivate intestinal CYP3A4 irreversibly, and quercetin inhibits the same enzyme reversibly along with several transporters. Taken together the effect on a co-administered substrate compounds rather than cancels. For anyone on a medication metabolised by CYP3A4 this is a reason for caution, not a benefit to seek. The individual mechanisms are well characterised. The combined magnitude in people is not quantified.

Both raise the systemic exposure of co-taken compounds by slowing first-pass metabolism and efflux at the gut wall. Stacking them makes the exposure change larger and harder to predict. Formulas that use piperine as an absorption enhancer should not assume grapefruit juice is a neutral background. This matters most for anything with a narrow dosing window.

Hyperforin activates the pregnane X receptor and increases CYP3A4 and P-glycoprotein expression over days to weeks. Grapefruit furanocoumarins destroy existing enzyme within hours. Combining them does not cancel out cleanly because the timescales differ completely, and the net exposure of any third compound becomes unpredictable. Both are individually among the most consequential botanical interaction agents there are.

The fruit contributes ascorbate directly, so a supplement taken alongside it adds to the same intake total. This is straightforward nutrient arithmetic. It is worth noting only because grapefruit is usually discussed for its interaction chemistry and rarely for its nutrient content. The ascorbate has nothing to do with the furanocoumarin effect.

A combination of the two extracts was examined for effects on skin cells and photodamage markers in laboratory systems. Rosemary contributes carnosic acid and rosmarinic acid, grapefruit contributes naringin and related flavanones. The work is non-human and measures markers rather than outcomes people would notice. The pairing is a formulated combination rather than a demonstrated physiological synergy.

Ascorbate reduces ferric iron to the ferrous form and citric acid keeps it soluble through the duodenum, both of which raise the fraction absorbed. Citrus taken with a plant-source iron meal is the classic worked example of this. The effect is on non-haem iron specifically. It is unrelated to the CYP interaction grapefruit is known for.

Oral melatonin undergoes heavy first-pass metabolism, so anything that slows the enzymes handling it could raise circulating levels from an unchanged dose. Reported clinical work shows repeated grapefruit intake inhibits several CYP isoforms, though melatonin's own main clearance route was not among those measured. Whether that translates into a stronger or longer melatonin effect in people has not been tested directly. Anyone titrating melatonin may prefer to keep grapefruit intake consistent.

Grapefruit inhibits both intestinal CYP3A4 and, through naringin, some transporter activity at the gut wall. Berberine depends on those same systems for its low and variable bioavailability. Combining them raises exposure in an uncontrolled way. This makes dose comparisons across people unreliable rather than delivering a designed benefit.

Naringin and furanocoumarins alter intestinal transporter activity, which shifts how much of an oral CoQ10 dose crosses the enterocyte. The direction depends on which transporter dominates for the formulation in question. Human data on this specific pair is absent. Regard it as mechanistic plausibility, not a dosing recommendation.